Global Tourette Syndrome- Market

Tourette Syndrome- Comprehensive Study by Type (Antipsychotics, Non-antipsychotics), Drug Type (Fluphenazine, Haloperidol, Risperidone, Pimozide, Tetrabenazine, Botulinum (Botox) Injections, Methylphenidate, Dextroamphetamine, Clonidine, Guanfacine, Fluoxetine), Type (Motor Tics, Vocal Tics), Daignosis (Blood Diagnosis, Imaging Diagnosis, Others), Therapy Type (Behavior Therapy, Psychotherapy, Deep Brain Stimulation (DBS), Comprehensive Behavioral Intervention for Tics (CBIT), Others), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

Tourette Syndrome- Market by XX Submarkets | Forecast Years 2025-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Tourette Syndrome- Market Scope
The market encompasses various pharmaceutical drugs, therapeutic interventions, diagnostic tests, and supportive care options to alleviate symptoms and improve the quality of life for individuals with Tourette syndrome. It refers to the market for products and services related to diagnosing, treating, and managing Tourette syndrome, a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics. The growing awareness about tourette syndrome is one of the major factors driving the growth of tourette syndrome market. The increase in neurotransmitter disorders and healthcare infrastructure expenditure accelerate the tourette syndrome market growth. Tourette syndrome often begins in childhood and continues into adulthood, although the severity of symptoms may decrease over time for some individuals. In addition to tics, they may also experience other conditions, such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). The diagnosis of the ailment is based on a thorough evaluation of the patient's symptoms and medical history. To be diagnosed with TS, an individual must have both motor and vocal tics that have been present for at least one year, with onset before age 18. The tics must be involuntary and not the result of other medical conditions, such as a medication side effect or another neurological disorder. The healthcare professional may also use diagnostic tools, including imaging studies or blood tests, to rule out other possible causes of the symptoms.

AttributesDetails
Study Period2020-2030
Base Year2024
UnitValue (USD Million)
Key Companies ProfiledTeva Pharmaceutical Industries Ltd. (United States), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (United States), Otsuka Holdings Co. Ltd. (Japan), Mylan N.V. (United States), Johnson & Johnson Services Inc. (United States), H. Lundbeck A/S (United States), Eli Lilly and Company. (United States), Boehringer Ingelheim International GmbH (United States), AstraZeneca (United States), Catalyst Pharma (United States) and Neurocrine Biosciences, Inc. (United States)
CAGR%


The global tourette syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Global Tourette Syndrome Market. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Tourette Syndrome- market throughout the predicted period.

Teva Pharmaceutical Industries Ltd. (United States), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (United States), Otsuka Holdings Co. Ltd. (Japan), Mylan N.V. (United States), Johnson & Johnson Services Inc. (United States), H. Lundbeck A/S (United States), Eli Lilly and Company. (United States), Boehringer Ingelheim International GmbH (United States), AstraZeneca (United States), Catalyst Pharma (United States) and Neurocrine Biosciences, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Emalex Biosciences Inc. (United States), Beijing PINS Medical Co., Ltd. (Japan),, FGK Clinical Research GmbH (Germany), Medtronic (United States) and Bausch Health Companies Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Tourette Syndrome- market by Type and Region with country level break-up.

On the basis of geography, the market of Tourette Syndrome- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2024.

Market Leaders and their expansionary development strategies
In June 2024, The Tourette Association of America (TAA) organized its annual national conference. This event provided a platform for individuals affected by TS and tic disorders to learn, connect, and engage in various activities.
In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the company’s strong commercial portfolio with AUSTEDO, AJOVY, UZEDYTM, and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse, and focus the business


Influencing Trend:
Increasing prevalence of inherited neurological disorders

Market Growth Drivers:
Increasing Awareness and Diagnosis and Increasing Demand for Therapeutic Interventions

Challenges:
High cost of daignosis

Restraints:
Limited understanding of the underlying cause

Opportunities:
Advancements in medical research and Rising cases of delivery complications, such as meconium-stained amniotic fluid and premature rupture of the membranes

Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

Report Objectives / Segmentation Covered

By Type
  • Antipsychotics
  • Non-antipsychotics
By Drug Type
  • Fluphenazine
  • Haloperidol
  • Risperidone
  • Pimozide
  • Tetrabenazine
  • Botulinum (Botox) Injections
  • Methylphenidate
  • Dextroamphetamine
  • Clonidine
  • Guanfacine
  • Fluoxetine

By Type
  • Motor Tics
  • Vocal Tics

By Daignosis
  • Blood Diagnosis
  • Imaging Diagnosis
  • Others

By Therapy Type
  • Behavior Therapy
  • Psychotherapy
  • Deep Brain Stimulation (DBS)
  • Comprehensive Behavioral Intervention for Tics (CBIT)
  • Others

By End User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Awareness and Diagnosis
      • 3.2.2. Increasing Demand for Therapeutic Interventions
    • 3.3. Market Challenges
      • 3.3.1. High cost of daignosis
    • 3.4. Market Trends
      • 3.4.1. Increasing prevalence of inherited neurological disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tourette Syndrome-, by Type, Drug Type, Type, Daignosis, Therapy Type, End User and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Tourette Syndrome- (Value)
      • 5.2.1. Global Tourette Syndrome- by: Type (Value)
        • 5.2.1.1. Antipsychotics
        • 5.2.1.2. Non-antipsychotics
      • 5.2.2. Global Tourette Syndrome- by: Type (Value)
        • 5.2.2.1. Motor Tics
        • 5.2.2.2. Vocal Tics
      • 5.2.3. Global Tourette Syndrome- by: Drug Type (Value)
        • 5.2.3.1. Fluphenazine
        • 5.2.3.2. Haloperidol
        • 5.2.3.3. Risperidone
        • 5.2.3.4. Pimozide
        • 5.2.3.5. Tetrabenazine
        • 5.2.3.6. Botulinum (Botox) Injections
        • 5.2.3.7. Methylphenidate
        • 5.2.3.8. Dextroamphetamine
        • 5.2.3.9. Clonidine
        • 5.2.3.10. Guanfacine
        • 5.2.3.11. Fluoxetine
      • 5.2.4. Global Tourette Syndrome- by: Type (Value)
        • 5.2.4.1. Antipsychotics
        • 5.2.4.2. Non-antipsychotics
      • 5.2.5. Global Tourette Syndrome- by: Type (Value)
        • 5.2.5.1. Motor Tics
        • 5.2.5.2. Vocal Tics
      • 5.2.6. Global Tourette Syndrome- by: Daignosis (Value)
        • 5.2.6.1. Blood Diagnosis
        • 5.2.6.2. Imaging Diagnosis
        • 5.2.6.3. Others
      • 5.2.7. Global Tourette Syndrome- by: Therapy Type (Value)
        • 5.2.7.1. Behavior Therapy
        • 5.2.7.2. Psychotherapy
        • 5.2.7.3. Deep Brain Stimulation (DBS)
        • 5.2.7.4. Comprehensive Behavioral Intervention for Tics (CBIT)
        • 5.2.7.5. Others
      • 5.2.8. Global Tourette Syndrome- by: End User (Value)
        • 5.2.8.1. Hospitals
        • 5.2.8.2. Clinics
        • 5.2.8.3. Others
      • 5.2.9. Global Tourette Syndrome- Region
        • 5.2.9.1. South America
          • 5.2.9.1.1. Brazil
          • 5.2.9.1.2. Argentina
          • 5.2.9.1.3. Rest of South America
        • 5.2.9.2. Asia Pacific
          • 5.2.9.2.1. China
          • 5.2.9.2.2. Japan
          • 5.2.9.2.3. India
          • 5.2.9.2.4. South Korea
          • 5.2.9.2.5. Taiwan
          • 5.2.9.2.6. Australia
          • 5.2.9.2.7. Rest of Asia-Pacific
        • 5.2.9.3. Europe
          • 5.2.9.3.1. Germany
          • 5.2.9.3.2. France
          • 5.2.9.3.3. Italy
          • 5.2.9.3.4. United Kingdom
          • 5.2.9.3.5. Netherlands
          • 5.2.9.3.6. Rest of Europe
        • 5.2.9.4. MEA
          • 5.2.9.4.1. Middle East
          • 5.2.9.4.2. Africa
        • 5.2.9.5. North America
          • 5.2.9.5.1. United States
          • 5.2.9.5.2. Canada
          • 5.2.9.5.3. Mexico
  • 6. Tourette Syndrome-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries Ltd. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Otsuka Holdings Co. Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mylan N.V. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Services Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. H. Lundbeck A/S (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim International GmbH (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Catalyst Pharma (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Neurocrine Biosciences, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Tourette Syndrome- Sale, by Type, Drug Type, Type, Daignosis, Therapy Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Tourette Syndrome- (Value)
      • 7.2.1. Global Tourette Syndrome- by: Type (Value)
        • 7.2.1.1. Antipsychotics
        • 7.2.1.2. Non-antipsychotics
      • 7.2.2. Global Tourette Syndrome- by: Type (Value)
        • 7.2.2.1. Motor Tics
        • 7.2.2.2. Vocal Tics
      • 7.2.3. Global Tourette Syndrome- by: Drug Type (Value)
        • 7.2.3.1. Fluphenazine
        • 7.2.3.2. Haloperidol
        • 7.2.3.3. Risperidone
        • 7.2.3.4. Pimozide
        • 7.2.3.5. Tetrabenazine
        • 7.2.3.6. Botulinum (Botox) Injections
        • 7.2.3.7. Methylphenidate
        • 7.2.3.8. Dextroamphetamine
        • 7.2.3.9. Clonidine
        • 7.2.3.10. Guanfacine
        • 7.2.3.11. Fluoxetine
      • 7.2.4. Global Tourette Syndrome- by: Type (Value)
        • 7.2.4.1. Antipsychotics
        • 7.2.4.2. Non-antipsychotics
      • 7.2.5. Global Tourette Syndrome- by: Type (Value)
        • 7.2.5.1. Motor Tics
        • 7.2.5.2. Vocal Tics
      • 7.2.6. Global Tourette Syndrome- by: Daignosis (Value)
        • 7.2.6.1. Blood Diagnosis
        • 7.2.6.2. Imaging Diagnosis
        • 7.2.6.3. Others
      • 7.2.7. Global Tourette Syndrome- by: Therapy Type (Value)
        • 7.2.7.1. Behavior Therapy
        • 7.2.7.2. Psychotherapy
        • 7.2.7.3. Deep Brain Stimulation (DBS)
        • 7.2.7.4. Comprehensive Behavioral Intervention for Tics (CBIT)
        • 7.2.7.5. Others
      • 7.2.8. Global Tourette Syndrome- by: End User (Value)
        • 7.2.8.1. Hospitals
        • 7.2.8.2. Clinics
        • 7.2.8.3. Others
      • 7.2.9. Global Tourette Syndrome- Region
        • 7.2.9.1. South America
          • 7.2.9.1.1. Brazil
          • 7.2.9.1.2. Argentina
          • 7.2.9.1.3. Rest of South America
        • 7.2.9.2. Asia Pacific
          • 7.2.9.2.1. China
          • 7.2.9.2.2. Japan
          • 7.2.9.2.3. India
          • 7.2.9.2.4. South Korea
          • 7.2.9.2.5. Taiwan
          • 7.2.9.2.6. Australia
          • 7.2.9.2.7. Rest of Asia-Pacific
        • 7.2.9.3. Europe
          • 7.2.9.3.1. Germany
          • 7.2.9.3.2. France
          • 7.2.9.3.3. Italy
          • 7.2.9.3.4. United Kingdom
          • 7.2.9.3.5. Netherlands
          • 7.2.9.3.6. Rest of Europe
        • 7.2.9.4. MEA
          • 7.2.9.4.1. Middle East
          • 7.2.9.4.2. Africa
        • 7.2.9.5. North America
          • 7.2.9.5.1. United States
          • 7.2.9.5.2. Canada
          • 7.2.9.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tourette Syndrome-: by Type(USD Million)
  • Table 2. Tourette Syndrome- Antipsychotics , by Region USD Million (2019-2024)
  • Table 3. Tourette Syndrome- Non-antipsychotics , by Region USD Million (2019-2024)
  • Table 4. Tourette Syndrome-: by Type(USD Million)
  • Table 5. Tourette Syndrome- Motor Tics , by Region USD Million (2019-2024)
  • Table 6. Tourette Syndrome- Vocal Tics , by Region USD Million (2019-2024)
  • Table 7. Tourette Syndrome-: by Drug Type(USD Million)
  • Table 8. Tourette Syndrome- Fluphenazine , by Region USD Million (2019-2024)
  • Table 9. Tourette Syndrome- Haloperidol , by Region USD Million (2019-2024)
  • Table 10. Tourette Syndrome- Risperidone , by Region USD Million (2019-2024)
  • Table 11. Tourette Syndrome- Pimozide , by Region USD Million (2019-2024)
  • Table 12. Tourette Syndrome- Tetrabenazine , by Region USD Million (2019-2024)
  • Table 13. Tourette Syndrome- Botulinum (Botox) Injections , by Region USD Million (2019-2024)
  • Table 14. Tourette Syndrome- Methylphenidate , by Region USD Million (2019-2024)
  • Table 15. Tourette Syndrome- Dextroamphetamine , by Region USD Million (2019-2024)
  • Table 16. Tourette Syndrome- Clonidine , by Region USD Million (2019-2024)
  • Table 17. Tourette Syndrome- Guanfacine , by Region USD Million (2019-2024)
  • Table 18. Tourette Syndrome- Fluoxetine , by Region USD Million (2019-2024)
  • Table 19. Tourette Syndrome-: by Type(USD Million)
  • Table 20. Tourette Syndrome- Antipsychotics , by Region USD Million (2019-2024)
  • Table 21. Tourette Syndrome- Non-antipsychotics , by Region USD Million (2019-2024)
  • Table 22. Tourette Syndrome-: by Type(USD Million)
  • Table 23. Tourette Syndrome- Motor Tics , by Region USD Million (2019-2024)
  • Table 24. Tourette Syndrome- Vocal Tics , by Region USD Million (2019-2024)
  • Table 25. Tourette Syndrome-: by Daignosis(USD Million)
  • Table 26. Tourette Syndrome- Blood Diagnosis , by Region USD Million (2019-2024)
  • Table 27. Tourette Syndrome- Imaging Diagnosis , by Region USD Million (2019-2024)
  • Table 28. Tourette Syndrome- Others , by Region USD Million (2019-2024)
  • Table 29. Tourette Syndrome-: by Therapy Type(USD Million)
  • Table 30. Tourette Syndrome- Behavior Therapy , by Region USD Million (2019-2024)
  • Table 31. Tourette Syndrome- Psychotherapy , by Region USD Million (2019-2024)
  • Table 32. Tourette Syndrome- Deep Brain Stimulation (DBS) , by Region USD Million (2019-2024)
  • Table 33. Tourette Syndrome- Comprehensive Behavioral Intervention for Tics (CBIT) , by Region USD Million (2019-2024)
  • Table 34. Tourette Syndrome- Others , by Region USD Million (2019-2024)
  • Table 35. Tourette Syndrome-: by End User(USD Million)
  • Table 36. Tourette Syndrome- Hospitals , by Region USD Million (2019-2024)
  • Table 37. Tourette Syndrome- Clinics , by Region USD Million (2019-2024)
  • Table 38. Tourette Syndrome- Others , by Region USD Million (2019-2024)
  • Table 39. South America Tourette Syndrome-, by Country USD Million (2019-2024)
  • Table 40. South America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 41. South America Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 42. South America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 43. South America Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 44. South America Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 45. South America Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 46. Brazil Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 47. Brazil Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 48. Brazil Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 49. Brazil Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 50. Brazil Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 51. Brazil Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 52. Argentina Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 53. Argentina Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 54. Argentina Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 55. Argentina Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 56. Argentina Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 57. Argentina Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 58. Rest of South America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 59. Rest of South America Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 60. Rest of South America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 61. Rest of South America Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 62. Rest of South America Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 63. Rest of South America Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 64. Asia Pacific Tourette Syndrome-, by Country USD Million (2019-2024)
  • Table 65. Asia Pacific Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 66. Asia Pacific Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 67. Asia Pacific Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 68. Asia Pacific Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 69. Asia Pacific Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 70. Asia Pacific Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 71. China Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 72. China Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 73. China Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 74. China Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 75. China Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 76. China Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 77. Japan Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 78. Japan Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 79. Japan Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 80. Japan Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 81. Japan Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 82. Japan Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 83. India Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 84. India Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 85. India Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 86. India Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 87. India Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 88. India Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 89. South Korea Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 90. South Korea Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 91. South Korea Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 92. South Korea Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 93. South Korea Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 94. South Korea Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 95. Taiwan Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 96. Taiwan Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 97. Taiwan Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 98. Taiwan Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 99. Taiwan Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 100. Taiwan Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 101. Australia Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 102. Australia Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 103. Australia Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 104. Australia Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 105. Australia Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 106. Australia Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 107. Rest of Asia-Pacific Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 108. Rest of Asia-Pacific Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 109. Rest of Asia-Pacific Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 110. Rest of Asia-Pacific Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 111. Rest of Asia-Pacific Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 112. Rest of Asia-Pacific Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 113. Europe Tourette Syndrome-, by Country USD Million (2019-2024)
  • Table 114. Europe Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 115. Europe Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 116. Europe Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 117. Europe Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 118. Europe Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 119. Europe Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 120. Germany Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 121. Germany Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 122. Germany Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 123. Germany Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 124. Germany Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 125. Germany Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 126. France Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 127. France Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 128. France Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 129. France Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 130. France Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 131. France Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 132. Italy Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 133. Italy Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 134. Italy Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 135. Italy Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 136. Italy Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 137. Italy Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 138. United Kingdom Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 139. United Kingdom Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 140. United Kingdom Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 141. United Kingdom Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 142. United Kingdom Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 143. United Kingdom Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 144. Netherlands Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 145. Netherlands Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 146. Netherlands Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 147. Netherlands Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 148. Netherlands Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 149. Netherlands Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 150. Rest of Europe Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 151. Rest of Europe Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 152. Rest of Europe Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 153. Rest of Europe Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 154. Rest of Europe Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 155. Rest of Europe Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 156. MEA Tourette Syndrome-, by Country USD Million (2019-2024)
  • Table 157. MEA Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 158. MEA Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 159. MEA Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 160. MEA Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 161. MEA Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 162. MEA Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 163. Middle East Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 164. Middle East Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 165. Middle East Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 166. Middle East Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 167. Middle East Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 168. Middle East Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 169. Africa Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 170. Africa Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 171. Africa Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 172. Africa Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 173. Africa Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 174. Africa Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 175. North America Tourette Syndrome-, by Country USD Million (2019-2024)
  • Table 176. North America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 177. North America Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 178. North America Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 179. North America Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 180. North America Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 181. North America Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 182. United States Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 183. United States Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 184. United States Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 185. United States Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 186. United States Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 187. United States Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 188. Canada Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 189. Canada Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 190. Canada Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 191. Canada Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 192. Canada Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 193. Canada Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 194. Mexico Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 195. Mexico Tourette Syndrome-, by Drug Type USD Million (2019-2024)
  • Table 196. Mexico Tourette Syndrome-, by Type USD Million (2019-2024)
  • Table 197. Mexico Tourette Syndrome-, by Daignosis USD Million (2019-2024)
  • Table 198. Mexico Tourette Syndrome-, by Therapy Type USD Million (2019-2024)
  • Table 199. Mexico Tourette Syndrome-, by End User USD Million (2019-2024)
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Tourette Syndrome-: by Type(USD Million)
  • Table 213. Tourette Syndrome- Antipsychotics , by Region USD Million (2025-2030)
  • Table 214. Tourette Syndrome- Non-antipsychotics , by Region USD Million (2025-2030)
  • Table 215. Tourette Syndrome-: by Type(USD Million)
  • Table 216. Tourette Syndrome- Motor Tics , by Region USD Million (2025-2030)
  • Table 217. Tourette Syndrome- Vocal Tics , by Region USD Million (2025-2030)
  • Table 218. Tourette Syndrome-: by Drug Type(USD Million)
  • Table 219. Tourette Syndrome- Fluphenazine , by Region USD Million (2025-2030)
  • Table 220. Tourette Syndrome- Haloperidol , by Region USD Million (2025-2030)
  • Table 221. Tourette Syndrome- Risperidone , by Region USD Million (2025-2030)
  • Table 222. Tourette Syndrome- Pimozide , by Region USD Million (2025-2030)
  • Table 223. Tourette Syndrome- Tetrabenazine , by Region USD Million (2025-2030)
  • Table 224. Tourette Syndrome- Botulinum (Botox) Injections , by Region USD Million (2025-2030)
  • Table 225. Tourette Syndrome- Methylphenidate , by Region USD Million (2025-2030)
  • Table 226. Tourette Syndrome- Dextroamphetamine , by Region USD Million (2025-2030)
  • Table 227. Tourette Syndrome- Clonidine , by Region USD Million (2025-2030)
  • Table 228. Tourette Syndrome- Guanfacine , by Region USD Million (2025-2030)
  • Table 229. Tourette Syndrome- Fluoxetine , by Region USD Million (2025-2030)
  • Table 230. Tourette Syndrome-: by Type(USD Million)
  • Table 231. Tourette Syndrome- Antipsychotics , by Region USD Million (2025-2030)
  • Table 232. Tourette Syndrome- Non-antipsychotics , by Region USD Million (2025-2030)
  • Table 233. Tourette Syndrome-: by Type(USD Million)
  • Table 234. Tourette Syndrome- Motor Tics , by Region USD Million (2025-2030)
  • Table 235. Tourette Syndrome- Vocal Tics , by Region USD Million (2025-2030)
  • Table 236. Tourette Syndrome-: by Daignosis(USD Million)
  • Table 237. Tourette Syndrome- Blood Diagnosis , by Region USD Million (2025-2030)
  • Table 238. Tourette Syndrome- Imaging Diagnosis , by Region USD Million (2025-2030)
  • Table 239. Tourette Syndrome- Others , by Region USD Million (2025-2030)
  • Table 240. Tourette Syndrome-: by Therapy Type(USD Million)
  • Table 241. Tourette Syndrome- Behavior Therapy , by Region USD Million (2025-2030)
  • Table 242. Tourette Syndrome- Psychotherapy , by Region USD Million (2025-2030)
  • Table 243. Tourette Syndrome- Deep Brain Stimulation (DBS) , by Region USD Million (2025-2030)
  • Table 244. Tourette Syndrome- Comprehensive Behavioral Intervention for Tics (CBIT) , by Region USD Million (2025-2030)
  • Table 245. Tourette Syndrome- Others , by Region USD Million (2025-2030)
  • Table 246. Tourette Syndrome-: by End User(USD Million)
  • Table 247. Tourette Syndrome- Hospitals , by Region USD Million (2025-2030)
  • Table 248. Tourette Syndrome- Clinics , by Region USD Million (2025-2030)
  • Table 249. Tourette Syndrome- Others , by Region USD Million (2025-2030)
  • Table 250. South America Tourette Syndrome-, by Country USD Million (2025-2030)
  • Table 251. South America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 252. South America Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 253. South America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 254. South America Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 255. South America Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 256. South America Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 257. Brazil Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 258. Brazil Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 259. Brazil Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 260. Brazil Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 261. Brazil Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 262. Brazil Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 263. Argentina Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 264. Argentina Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 265. Argentina Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 266. Argentina Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 267. Argentina Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 268. Argentina Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 269. Rest of South America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 270. Rest of South America Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 271. Rest of South America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 272. Rest of South America Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 273. Rest of South America Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 274. Rest of South America Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 275. Asia Pacific Tourette Syndrome-, by Country USD Million (2025-2030)
  • Table 276. Asia Pacific Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 277. Asia Pacific Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 278. Asia Pacific Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 279. Asia Pacific Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 280. Asia Pacific Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 281. Asia Pacific Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 282. China Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 283. China Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 284. China Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 285. China Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 286. China Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 287. China Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 288. Japan Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 289. Japan Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 290. Japan Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 291. Japan Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 292. Japan Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 293. Japan Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 294. India Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 295. India Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 296. India Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 297. India Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 298. India Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 299. India Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 300. South Korea Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 301. South Korea Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 302. South Korea Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 303. South Korea Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 304. South Korea Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 305. South Korea Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 306. Taiwan Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 307. Taiwan Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 308. Taiwan Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 309. Taiwan Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 310. Taiwan Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 311. Taiwan Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 312. Australia Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 313. Australia Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 314. Australia Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 315. Australia Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 316. Australia Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 317. Australia Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 318. Rest of Asia-Pacific Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 319. Rest of Asia-Pacific Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 320. Rest of Asia-Pacific Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 324. Europe Tourette Syndrome-, by Country USD Million (2025-2030)
  • Table 325. Europe Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 326. Europe Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 327. Europe Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 328. Europe Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 329. Europe Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 330. Europe Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 331. Germany Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 332. Germany Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 333. Germany Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 334. Germany Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 335. Germany Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 336. Germany Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 337. France Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 338. France Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 339. France Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 340. France Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 341. France Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 342. France Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 343. Italy Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 344. Italy Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 345. Italy Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 346. Italy Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 347. Italy Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 348. Italy Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 349. United Kingdom Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 350. United Kingdom Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 351. United Kingdom Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 352. United Kingdom Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 353. United Kingdom Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 354. United Kingdom Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 355. Netherlands Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 356. Netherlands Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 357. Netherlands Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 358. Netherlands Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 359. Netherlands Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 360. Netherlands Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 361. Rest of Europe Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 362. Rest of Europe Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 363. Rest of Europe Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 364. Rest of Europe Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 365. Rest of Europe Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 366. Rest of Europe Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 367. MEA Tourette Syndrome-, by Country USD Million (2025-2030)
  • Table 368. MEA Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 369. MEA Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 370. MEA Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 371. MEA Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 372. MEA Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 373. MEA Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 374. Middle East Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 375. Middle East Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 376. Middle East Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 377. Middle East Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 378. Middle East Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 379. Middle East Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 380. Africa Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 381. Africa Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 382. Africa Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 383. Africa Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 384. Africa Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 385. Africa Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 386. North America Tourette Syndrome-, by Country USD Million (2025-2030)
  • Table 387. North America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 388. North America Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 389. North America Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 390. North America Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 391. North America Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 392. North America Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 393. United States Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 394. United States Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 395. United States Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 396. United States Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 397. United States Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 398. United States Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 399. Canada Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 400. Canada Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 401. Canada Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 402. Canada Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 403. Canada Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 404. Canada Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 405. Mexico Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 406. Mexico Tourette Syndrome-, by Drug Type USD Million (2025-2030)
  • Table 407. Mexico Tourette Syndrome-, by Type USD Million (2025-2030)
  • Table 408. Mexico Tourette Syndrome-, by Daignosis USD Million (2025-2030)
  • Table 409. Mexico Tourette Syndrome-, by Therapy Type USD Million (2025-2030)
  • Table 410. Mexico Tourette Syndrome-, by End User USD Million (2025-2030)
  • Table 411. Research Programs/Design for This Report
  • Table 412. Key Data Information from Secondary Sources
  • Table 413. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tourette Syndrome-: by Type USD Million (2019-2024)
  • Figure 5. Global Tourette Syndrome-: by Type USD Million (2019-2024)
  • Figure 6. Global Tourette Syndrome-: by Drug Type USD Million (2019-2024)
  • Figure 7. Global Tourette Syndrome-: by Type USD Million (2019-2024)
  • Figure 8. Global Tourette Syndrome-: by Type USD Million (2019-2024)
  • Figure 9. Global Tourette Syndrome-: by Daignosis USD Million (2019-2024)
  • Figure 10. Global Tourette Syndrome-: by Therapy Type USD Million (2019-2024)
  • Figure 11. Global Tourette Syndrome-: by End User USD Million (2019-2024)
  • Figure 12. South America Tourette Syndrome- Share (%), by Country
  • Figure 13. Asia Pacific Tourette Syndrome- Share (%), by Country
  • Figure 14. Europe Tourette Syndrome- Share (%), by Country
  • Figure 15. MEA Tourette Syndrome- Share (%), by Country
  • Figure 16. North America Tourette Syndrome- Share (%), by Country
  • Figure 17. Global Tourette Syndrome- share by Players 2024 (%)
  • Figure 18. Global Tourette Syndrome- share by Players (Top 3) 2024(%)
  • Figure 19. Global Tourette Syndrome- share by Players (Top 5) 2024(%)
  • Figure 20. BCG Matrix for key Companies
  • Figure 21. Teva Pharmaceutical Industries Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd. (United States) Revenue: by Geography 2024
  • Figure 23. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2024
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2024
  • Figure 27. Otsuka Holdings Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Otsuka Holdings Co. Ltd. (Japan) Revenue: by Geography 2024
  • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2024
  • Figure 31. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2024
  • Figure 33. H. Lundbeck A/S (United States) Revenue, Net Income and Gross profit
  • Figure 34. H. Lundbeck A/S (United States) Revenue: by Geography 2024
  • Figure 35. Eli Lilly and Company. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company. (United States) Revenue: by Geography 2024
  • Figure 37. Boehringer Ingelheim International GmbH (United States) Revenue, Net Income and Gross profit
  • Figure 38. Boehringer Ingelheim International GmbH (United States) Revenue: by Geography 2024
  • Figure 39. AstraZeneca (United States) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca (United States) Revenue: by Geography 2024
  • Figure 41. Catalyst Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 42. Catalyst Pharma (United States) Revenue: by Geography 2024
  • Figure 43. Neurocrine Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Neurocrine Biosciences, Inc. (United States) Revenue: by Geography 2024
  • Figure 45. Global Tourette Syndrome-: by Type USD Million (2025-2030)
  • Figure 46. Global Tourette Syndrome-: by Type USD Million (2025-2030)
  • Figure 47. Global Tourette Syndrome-: by Drug Type USD Million (2025-2030)
  • Figure 48. Global Tourette Syndrome-: by Type USD Million (2025-2030)
  • Figure 49. Global Tourette Syndrome-: by Type USD Million (2025-2030)
  • Figure 50. Global Tourette Syndrome-: by Daignosis USD Million (2025-2030)
  • Figure 51. Global Tourette Syndrome-: by Therapy Type USD Million (2025-2030)
  • Figure 52. Global Tourette Syndrome-: by End User USD Million (2025-2030)
  • Figure 53. South America Tourette Syndrome- Share (%), by Country
  • Figure 54. Asia Pacific Tourette Syndrome- Share (%), by Country
  • Figure 55. Europe Tourette Syndrome- Share (%), by Country
  • Figure 56. MEA Tourette Syndrome- Share (%), by Country
  • Figure 57. North America Tourette Syndrome- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries Ltd. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Pfizer Inc. (United States)
  • Otsuka Holdings Co. Ltd. (Japan)
  • Mylan N.V. (United States)
  • Johnson & Johnson Services Inc. (United States)
  • H. Lundbeck A/S (United States)
  • Eli Lilly and Company. (United States)
  • Boehringer Ingelheim International GmbH (United States)
  • AstraZeneca (United States)
  • Catalyst Pharma (United States)
  • Neurocrine Biosciences, Inc. (United States)
Additional players considered in the study are as follows:
Emalex Biosciences Inc. (United States) , Beijing PINS Medical Co., Ltd. (Japan), , FGK Clinical Research GmbH (Germany) , Medtronic (United States) , Bausch Health Companies Inc. (United States)
Select User Access Type

Key Highlights of Report


Feb 2025 231 Pages 81 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tourette Syndrome- Market Quantitative research analysis
Global Tourette Syndrome- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Tourette Syndrome- Market are by type [Antipsychotics and Non-antipsychotics], by end use application [].
The Tourette Syndrome- Market is gaining popularity and expected to see strong valuation by 2030.
  • Increasing Awareness and Diagnosis
  • Increasing Demand for Therapeutic Interventions

Know More About Global Tourette Syndrome- Market Report?

Have a Query? Click Here

Other Related Reports

AI-Based Robotic System for Medical Triage and Precise Diagnosis Comprehensive Study by Application (Robot-assisted Surgery, Virtual Assistants, Administrative Workflow Assistants, Connected Medical ...
$ 3800
Psychedelic Medicine Comprehensive Study by Application (Mental Health Disorders, Pain Management, End-of-Life Care, Existential Therapy), Drug Type (Psilocybin, Ketamine, MDMA, LSD, Ibogaine, Ayahua...
$ 3800